Compare TH & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TH | SRPT |
|---|---|---|
| Founded | 1978 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2017 | 2000 |
| Metric | TH | SRPT |
|---|---|---|
| Price | $16.13 | $15.77 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 29 |
| Target Price | $16.50 | ★ $25.85 |
| AVG Volume (30 Days) | 1.1M | ★ 3.6M |
| Earning Date | 05-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | $320,635,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $17.45 | N/A |
| Revenue Next Year | $38.19 | N/A |
| P/E Ratio | ★ N/A | $5.51 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $5.97 | $11.68 |
| 52 Week High | $20.85 | $25.32 |
| Indicator | TH | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 35.98 |
| Support Level | $15.95 | $15.55 |
| Resistance Level | $16.12 | $18.16 |
| Average True Range (ATR) | 0.69 | 0.93 |
| MACD | -0.22 | -0.35 |
| Stochastic Oscillator | 1.17 | 5.96 |
Target Hospitality Corp is a vertically integrated specialty rental and hospitality services company in the United States. The company provides vertically integrated specialty rental and comprehensive hospitality services, including catering food services, maintenance, housekeeping, grounds-keeping, on-site security, overall workforce lodge management, and laundry service. The company has three reportable segments: HFS - South, which provides specialty rental and hospitality services to the natural resources and development industry; WHS, which provides construction and hospitality solutions for critical mineral and data center projects; and Government, which provides specialty rental and hospitality services under government contracts.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.